← Latest news 
Novo Nordisk relaunches diabetes pills as Ozempic to win market share from Eli Lilly
Business
Published on 1 May 2026
A tablet is being pushed under the Ozempic brand
Novo Nordisk is relaunching a diabetes tablet in the United States under the Ozempic name, starting with select adult doses this Monday. The strategy banks on Ozempic’s blockbuster brand recognition to lift sales and help Novo regain market share from rival Eli Lilly as competition intensifies in diabetes care.
- Novo Nordisk is relaunching a diabetes tablet as Ozempic in the US
- Select adult doses begin availability starting Monday
- The move aims to boost sales using Ozempic brand recognition
- Novo is targeting market share against Eli Lilly
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times